You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!Submit Review
(+)-UH 232 maleate
D2 antagonist (Ki = 72.7 nM in a ligand binding assay; apparent KB = 14.5 nM in a cAMP accumulation assay); displays preferential activity at central dopamine autoreceptors. Stimulates a marked acceleration of dopamine synthesis and turnover. Produces locomotor stimulation. Exhibits little or no activity at central noradrenalin and 5-HT receptors. Also D3 partial agonist.
|Storage||Store at RT|
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
Tocris products are intended for laboratory research use only, unless stated otherwise.
|Solvent||Max Conc. mg/mL||Max Conc. mM|
Preparing Stock Solutions
The following data is based on the product molecular weight 391.51. Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|0.5 mM||5.11 mL||25.54 mL||51.08 mL|
|2.5 mM||1.02 mL||5.11 mL||10.22 mL|
|5 mM||0.51 mL||2.55 mL||5.11 mL|
|25 mM||0.1 mL||0.51 mL||1.02 mL|
References are publications that support the biological activity of the product.
Griffon et al (1995) The preferential DA D3 receptor ligand, (+)-UH 232, is a partial agonist. Eur.J.Pharmacol. 282 R3 PMID: 7498261
Hall and Strange (1997) Evidence that antipsychotic drugs are inverse agonists at D2 DA receptors. Br. J. Pharmacol. 121 731 PMID: 9208141
Johansson et al (1985) Novel DA receptor agonists and antagonists with preferential action on autoreceptors. J.Med.Chem. 28 1049 PMID: 3927002
Svensson et al (1986) (+)-AJ 76 and (+)-UH 232: central stimulants acting as preferential DA autoreceptor antagonists. Naunyn Schmiedebergs Arch.Pharmacol. 334 234 PMID: 2880302
If you know of a relevant reference for (+)-UH 232 maleate, please let us know.
View Related Products by Product Action
Keywords: (+)-UH 232 maleate, (+)-UH 232 maleate supplier, D2-like, autoreceptor, antagonists, D3, partial, agonists, Dopamine, Non-Selective, Receptors, dopaminergic, (+)-UH232, maleate, Non-selective, D2, 0775, Tocris Bioscience
Citations for (+)-UH 232 maleate
Citations are publications that use Tocris products.
Currently there are no citations for (+)-UH 232 maleate. Do you know of a great paper that uses (+)-UH 232 maleate from Tocris? Please let us know.
Reviews for (+)-UH 232 maleate
There are currently no reviews for this product. Be the first to review (+)-UH 232 maleate and earn rewards!
Have you used (+)-UH 232 maleate?
Submit a review and receive an Amazon gift card.
$50/€35/£30/$50CAN/¥300 Yuan/¥5000 Yen for first to review with an image
$25/€18/£15/$25CAN/¥75 Yuan/¥1250 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
Literature in this Area
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* or download your copy today!
*Please note that Tocris will only send literature to established scientific business / institute addresses.
Dopamine Receptors Scientific Review
Written by Phillip Strange and revised by Kim Neve in 2013, this review summarizes the history of the dopamine receptors and provides an overview of individual receptor subtype properties, their distribution and identifies ligands which act at each receptor subtype. Compounds available from Tocris are listed.
The key feature of drug addiction is the inability to stop using a drug despite clear evidence of harm. This poster describes the brain circuits associated with addiction, and provides an overview of the main classes of addictive drugs and the neurotransmitter systems that they target.
Major depressive disorder is characterized by depressed mood and a loss of interest and/or pleasure. Updated in 2015 this poster highlights presynaptic and postsynaptic targets for the potential treatment of major depressive disorder, as well as outlining the pharmacology of currently approved antidepressant drugs.
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.
Schizophrenia is a debilitating psychiatric disorder that affects 1% of the worldwide population. This poster describes the neurobiology of Schizophrenia, as well as highlighting the genetic and environmental factors that play a fundamental role in the etiology of the disease. The current and emerging drug targets are also discussed.